REVIEW
Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation
Nicholas J. Antos MD,
Adrienne P. Savant MD, MS,
Corresponding Author
Nicholas J. Antos MD
Department of Pediatrics, Division of Pulmonary and Sleep Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Department of Pediatric Pulmonology, Children's Wisconsin, Milwaukee, Wisconsin, USA
Correspondence Nicholas J. Antos, MD, Department of Pediatrics, Division of Pulmonary and Sleep Medicine, Medical College of Wisconsin, 9000 W Wisconsin Ave, PO Box 1997, Suite B620, Milwaukee, WI 53201, USA.
Email: [email protected]
Search for more papers by this authorAdrienne P. Savant MD, MS
Department of Pediatrics, Children's Hospital of New Orleans, New Orleans, Louisiana, USA
Department of Pediatrics, Tulane University, New Orleans, Louisiana, USA
Search for more papers by this authorNicholas J. Antos MD,
Adrienne P. Savant MD, MS,
Corresponding Author
Nicholas J. Antos MD
Department of Pediatrics, Division of Pulmonary and Sleep Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Department of Pediatric Pulmonology, Children's Wisconsin, Milwaukee, Wisconsin, USA
Correspondence Nicholas J. Antos, MD, Department of Pediatrics, Division of Pulmonary and Sleep Medicine, Medical College of Wisconsin, 9000 W Wisconsin Ave, PO Box 1997, Suite B620, Milwaukee, WI 53201, USA.
Email: [email protected]
Search for more papers by this authorAdrienne P. Savant MD, MS
Department of Pediatrics, Children's Hospital of New Orleans, New Orleans, Louisiana, USA
Department of Pediatrics, Tulane University, New Orleans, Louisiana, USA
Search for more papers by this authorAbstract
The outlook for those with cystic fibrosis (CF) has never been brighter with ever increasing life expectancy and the approval of the highly effective CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor. With that being said, the progressive pulmonary decline and importance of lung health, infection, and inflammation in CF remains. This review is the second part in a three-part CF Year in Review 2020. Part one focused on the literature related to CFTR modulators while part three will feature the multisystem effects related to CF. This review focuses on articles from Pediatric Pulmonology, including articles from other journals that are of particular interest to clinicians. Herein, we highlight studies published during 2020 related to CF pulmonary disease, infection, treatment, and diagnostics.
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
REFERENCES
- 1 Cystic Fibrosis Foundation Patient Registry. 2019 Annual Data Report. 2020. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf
- 2Filbrun AG, Enochs C, Caverly L, et al. Quality improvement initiative to improve pulmonary function in pediatric cystic fibrosis patients. Pediatr Pulmonol. 2020; 55: 3039-3045.
- 3Vandenbroucke NJ, Zampoli M, Morrow B. Lung function determinants and mortality of children and adolescents with cystic fibrosis in South Africa 2007-2016. Pediatr Pulmonol. 2020; 55: 1381-1387.
- 4Oates GR, Baker E, Rowe SM, et al. Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis. J Cyst Fibros. 2020; 19: 783-790.
- 5Leung GJ, Cho TJ, Kovesi T, Hamid JS, Radhakrishnan D. Variation in lung function and nutritional decline in cystic fibrosis by genotype: an analysis of the Canadian cystic fibrosis registry. J Cyst Fibros. 2020; 19: 255-261.
- 6Sanders DB, Ostrenga JS, Rosenfeld M, et al. Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020; 19: 407-414.
- 7Hoppe JE, Hinds DM, Colborg A, et al. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatr Pulmonol. 2020; 55: 3400-3406.
- 8Wagener JS, VanDevanter DR, Konstan MW, Pasta DJ, Millar SJ, Morgan WJ. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatr Pulmonol. 2020; 55: 828-834.
- 9Hizal M, Yalcin E, Alp A, et al. Respiratory viruses: what is their role in acute exacerbations in children with cystic fibrosis? Pediatr Pulmonol. 2020; 55: 1646-1652.
- 10Okoniewski W, Hughan KS, Weiner GA, Weiner DJ, Forno E. Glycemic control and FEV1 recovery during pulmonary exacerbations in pediatric cystic fibrosis-related diabetes. J Cyst Fibros. 2020; 19: 460-465.
- 11Singh A, He M, Chen V, et al. Blood biomarkers to predict short-term pulmonary exacerbation risk in children and adolescents with CF: a pilot study. J Cyst Fibros. 2020; 19: 49-51.
- 12Muirhead CA, Lanocha N, Markwardt S, MacDonald KD. Evaluation of rescue oral glucocorticoid therapy during inpatient cystic fibrosis exacerbations. Pediatr Pulmonol. 2020; 56: 891-900.
- 13Thomas CS, Brown RF. Sleep screening for cystic fibrosis patients: a survey of cystic fibrosis programs. Pediatr Pulmonol. 2020; 55: 3358-3363.
- 14Barbosa RRB, Liberato FMG, De Freitas Coelho P, Vidal PDR, De Carvalho R, Donadio MVF. Sleep-disordered breathing and markers of morbidity in children and adolescents with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 1974-1983.
- 15Gainey AB, Burch AK, Brownstein MJ, et al. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020; 55: 2990-2994.
- 16Lam GY, Goodwin J, Wilcox P, Quon BS. Worsening pulmonary outcomes during sex reassignment therapy in a transgender female with cystic fibrosis (CF) and asthma/allergic bronchopulmonary aspergillosis: a case report. BMC Pulm Med. 2020; 20: 234.
- 17Boyle M, Mulrennan S, Morey S, Vekaria S, Popowicz N, Tai A. Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis. Respirol Case Rep. 2021; 9:e00696.
- 18De Souza DC, Cogo LL, Palmeiro JK, et al. Thymidine-auxotrophic Staphylococcus aureus small-colony variant bacteremia in a patient with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 1388-1393.
- 19Nguyen TT, Condren M, Walter J. Ceftazidime-avibactam for the treatment of multidrug resistant Burkholderia cepacia complex in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020; 55: 283-284.
- 20Bentley S, Davies JC, Carr SB, Balfour-Lynn IM. Combination antifungal therapy for Scedosporium species in cystic fibrosis. Pediatr Pulmonol. 2020; 55(8): 1993-1995.
- 21Paul GR, Leber A, Nemastil CJ, et al. Identification of Mycobacterium porcinum in patients with cystic fibrosis: pathogen or contaminant? J Cyst Fibros. 2020; 19: 580-586.
- 22Rekis N, Ambrose M, Sakon C. Neurotoxicity in adult patients with cystic fibrosis using polymyxin B for acute pulmonary exacerbations. Pediatr Pulmonol. 2020; 55: 1094-1096.
- 23Svoboda E. Bacteria-eating viruses could provide a route to stability in cystic fibrosis. Nature. 2020; 583: S8-S9.
- 24Byars KC, Chini B, Hente E, Amin R, Boat T. Sleep disturbance and sleep insufficiency in primary caregivers and their children with cystic fibrosis. J Cyst Fibros. 2020; 19: 777-782.
- 25Epps QJ, Epps KL, Zobell JT, Young DC. Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: II. Therapies for allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 2020; 55: 3541-3572.
- 26Kapnadak SG, Dimango E, Hadjiliadis D, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros. 2020; 19: 344-354.
- 27Thirion DJG, Pasche V, Matouk E, Marsot A. Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. Pediatr Pulmonol. 2020; 55: 1154-1160.
- 28Cogen JD, Kahl BC, Maples H, et al. Finding the relevance of antimicrobial stewardship for cystic fibrosis. J Cyst Fibros. 2020; 19: 511-520.
- 29Lang RL, Stockton K, Wilson C, Russell TG, Johnston LM. Exercise testing for children with cystic fibrosis: a systematic review. Pediatr Pulmonol. 2020; 55: 1996-2010.
- 30Epps QJ, Epps KL, Young DC, Zobell JT. State of the art in cystic fibrosis pharmacology-optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics. Pediatr Pulmonol. 2020; 55: 33-57.
- 31Hoppe JE, Guimbellot J, Martiniano SL, et al. Highlights from the 2019 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2020; 55: 2225-2232.
- 32Rang C, Keating D, Wilson J, Kotsimbos T. Re-imagining cystic fibrosis care: next generation thinking. Eur Respir J. 2020; 55:1902443.
- 33Martiniano SL, Esther CR, Haworth CS, Kasperbauer SH, Zemanick ET, Caverly LJ. Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis. Pediatr Pulmonol. 2020; 55: 521-525.
- 34Puppo H, Torres-Castro R, Vasconcello-Castillo L, et al. Physical activity in children and adolescents with cystic fibrosis: a systematic review and meta-analysis. Pediatr Pulmonol. 2020; 55: 2863-2876.
- 35Solomon M, Mallory GB. Lung transplant referrals for individuals with cystic fibrosis: a pediatric perspective on the cystic fibrosis foundation consensus guidelines. Pediatr Pulmonol. 2020; 56: 465-471.
- 36Stephenson AL, Ramos KJ, Sykes J, et al. Bridging the survival gap in cystic fibrosis: an investigation of lung transplant outcomes in Canada and the United States. J Heart Lung Transplant. 2020; 40: 201-209.
- 37Perez AA, Hays SR, Soong A, et al. Improvements in frailty contribute to substantial improvements in quality of life after lung transplantation in patients with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 1406-1413.
- 38Frauchiger BS, Binggeli S, Yammine S, et al. Longitudinal course of clinical lung clearance index in children with cystic fibrosis. Eur Respir J. 2020.
- 39Davies G, Stanojevic S, Raywood E, et al. An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter. Eur Respir J. 2020; 56:2000006.
- 40Verger N, Arigliani M, Raywood E, et al. Limitations of regional ventilation inhomogeneity indices in children with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 2315-2322.
- 41Gambazza S, Guarise R, Carta F, et al. Exercise capacity and ventilation inhomogeneity in cystic fibrosis: a cross-sectional study. Pediatr Pulmonol. 2020; 55: 394-400.
- 42Walicka-Serzysko K, Postek M, Milczewska J, Sands D. Lung function deterioration in school children with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 3030-3038.
- 43Shaw M, Oppelaar MC, Jensen R, et al. The utility of moment ratios and abbreviated endpoints of the multiple breath washout test in preschool children with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 649-653.
- 44Skov L, Green K, Stanojevic S, et al. Lung compartment analysis assessed from N2 multiple-breath washout in children with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 1671-1680.
- 45Nusbaum K, Filigno SS, Feldstein J, et al. Assessing and responding to stress related to pulmonary function testing in cystic fibrosis through quality improvement. Pediatr Pulmonol. 2020; 55: 1139-1146.
- 46Bortoluzzi CF, Pontello E, Pintani E, et al. The impact of chest computed tomography and chest radiography on clinical management of cystic fibrosis lung disease. J Cyst Fibros. 2020; 19: 641-646.
- 47Rosenow T, Oudraad MC, Murray CP, et al. PRAGMA-CF. A quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis. Am J Respir Crit Care Med. 2015; 191: 1158-1165.
- 48Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr. 2009; 155: 623-8.
- 49Oudraad MCJ, Kuo W, Rosenow T, Andrinopoulou ER, Stick SM, Tiddens H. Assessment of early lung disease in young children with CF: a comparison between pressure-controlled and free-breathing chest computed tomography. Pediatr Pulmonol. 2020; 55: 1161-1168.
- 50Turkovic L, Caudri D, Rosenow T, et al. Structural determinants of long-term functional outcomes in young children with cystic fibrosis. Eur Respir J. 2020; 55:1900748.
- 51Bouma NR, Janssens HM, Andrinopoulou ER, Tiddens H. Airway disease on chest computed tomography of preschool children with cystic fibrosis is associated with school-age bronchiectasis. Pediatr Pulmonol. 2020; 55: 141-148.
- 52Robinson TE, Goris ML, Moss RB, et al. Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease. Pediatr Pulmonol. 2020; 55: 929-938.
- 53Laube BL, Carson KA, Evans CM, et al. Changes in mucociliary clearance over time in children with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 2307-2314.
- 54Thomen RP, Walkup LL, Roach DJ, et al. Regional structure-function in cystic fibrosis lung disease using hyperpolarized (129)Xe and ultrashort echo magnetic resonance imaging. Am J Respir Crit Care Med. 2020; 202: 290-292.
- 55Willmering MM, Roach DJ, Kramer EL, Walkup LL, Cleveland ZI, Woods JC. Sensitive structural and functional measurements and 1-year pulmonary outcomes in pediatric cystic fibrosis. J Cyst Fibros. 2020.
- 56Pennati F, Borzani I, Moroni L, et al. Longitudinal assessment of patients with cystic fibrosis lung disease with multivolume noncontrast MRI and spirometry. J Magn Reson Imaging. 2020; 53(5): 1570-1580.
- 57Couch MJ, Munidasa S, Rayment JH, et al. Free-breathing MRI for monitoring ventilation changes following antibiotic treatment of pulmonary exacerbations in pediatric cystic fibrosis. Eur Respir J. 2020.
- 58Meyer S, Nüßlein T, Nährlich L, et al. Infection prevention and control in patients with cystic fibrosis (CF): results from a survey in 35 German CF treatment centers. J Cyst Fibros. 2020; 19: 384-387.
- 59Milczewska J, Wołkowicz T, Zacharczuk K, et al. Clinical outcomes for cystic fibrosis patients with Pseudomonas aeruginosa cross-infections. Pediatr Pulmonol. 2020; 55: 161-168.
- 60Dennis JB, Jones AM, Davies EA, et al. Influenza B outbreak at an adult cystic fibrosis centre—clinical impact and factors influencing spread. J Cyst Fibros. 2020; 19: 808-814.
- 61Yan J, Kevat A, Martinez E, et al. Investigating transmission of Mycobacterium abscessus amongst children in an Australian cystic fibrosis centre. J Cyst Fibros. 2020; 19: 219-224.
- 62Hatziagorou E, Orenti A, Drevinek P, et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry. J Cyst Fibros. 2020; 19: 376-383.
- 63Millar BC, Maguire M, Moore RE, et al. Steam disinfection of toothbrushes from patients with cystic fibrosis: evidence-based recommendations. Pediatr Pulmonol. 2020; 55: 3012-3020.
- 64Zemanick E, Burgel PR, Taccetti G, et al. Antimicrobial resistance in cystic fibrosis: a Delphi approach to defining best practices. J Cyst Fibros. 2020; 19: 370-375.
- 65Branstetter J, Searcy H, Benner K, Yarbrough A, Crowder C, Troxler B. Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 3337-3342.
- 66Fusco NM, Meaney CJ, Frederick CA, Prescott WA Jr. Comparative Effectiveness of vancomycin versus linezolid for the treatment of acute pulmonary exacerbations of cystic fibrosis. Ann Pharmacother. 2020; 54: 197-204.
- 67Belarski E, Pettit R. Outcomes of a methicillin-resistant Staphylococcus aureus (MRSA) eradication protocol in pediatric cystic fibrosis (CF) patients. Pediatr Pulmonol. 2020; 55: 654-659.
- 68Galode F, Dournes G, Chateil JF, Fayon M, Collet C, Bui S. Impact at school age of early chronic methicillin-sensitive Staphylococcus aureus infection in children with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 2641-2645.
- 69Brockmeyer JM, Wise RT, Burgener EB, Milla C, Frymoyer A. Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care. Pediatr Pulmonol. 2020; 55: 3343-3350.
- 70Bilton D, Pressler T, Fajac I, et al. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros. 2020; 19: 284-291.
- 71Saad A, Young MR, Studtmann AE, et al. Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 3384-3390.
- 72Arrieta AC, Ang JY, Zhang Z, et al. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 2025-2032.
- 73Frost F, Young GR, Wright L, et al. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: an open-label randomised crossover study (AZTEC-CF). J Cyst Fibros. 2020.
- 74Hewer SCL, Smyth AR, Brown M, et al. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respir Med. 2020; 8: 975-986.
- 75Vermeulen F, Proesmans M, Vermaelen M, Boon M, De Boeck K. Isolation of Enterobacteriaceae in airway samples is associated with worse outcome in preschool children with cystic fibrosis. J Cyst Fibros. 2020; 19: 365-369.
- 76Koutsokera A, Corriveau S, Sykes J, et al. Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis. J Cyst Fibros. 2020; 19: 119-124.
- 77Pollak M, Shaw M, Wilson D, Grasemann H, Ratjen F. Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis. Eur Respir J. 2020; 56:2000175.
- 78Breuer O, Schultz A, Garratt LW, et al. Aspergillus infections and progression of structural lung disease in children with cystic fibrosis. Am J Respir Crit Care Med. 2020; 201: 688-696.
- 79Nichols DP, Moss RB. Early aspergillosis in cystic fibrosis and air trapping: guilt by association? Am J Respir Crit Care Med. 2020; 201: 644-645.
- 80Low D, Wilson DA, Flume PA. Screening practices for nontuberculous Mycobacteria at US cystic fibrosis centers. J Cyst Fibros. 2020; 19: 569-574.
- 81Reynaud Q, Bricca R, Cavalli Z, et al. Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: a meta-analysis. Pediatr Pulmonol. 2020; 55: 2653-2661.
- 82Azar M, Zimbric M, Shedden K, Caverly LJ. Distribution and outcomes of infection of Mycobacterium avium complex species in cystic fibrosis. J Cyst Fibros. 2020; 19: 232-235.
- 83Gruber W, Stehling F, Olivier M, et al. Effects of a long-term exercise program on motor performance in children and adolescents with CF. Pediatr Pulmonol. 2020; 55: 3371-3380.
- 84Dik J, Saglam M, Tekerlek H, et al. Visuomotor reaction time and dynamic balance in children with cystic fibrosis and non-cystic fibrosis bronchiectasis: A case-control study. Pediatr Pulmonol. 2020; 55: 2341-2347.
- 85Santuzzi CH, Liberato FMG, Morau SAC, De Oliveira NFF, Nascimento LR. Adherence and barriers to general and respiratory exercises in cystic fibrosis. Pediatr Pulmonol. 2020; 55: 2646-2652.
- 86Campos NE, Heinzmann-Filho JP, Becker NA, et al. Evaluation of the exercise intensity generated by active video gaming in patients with cystic fibrosis and healthy individuals. J Cyst Fibros. 2020; 19: 434-441.
- 87Avdimiretz N, Wilson D, Grasemann H. Comparison of a handheld turbine spirometer to conventional spirometry in children with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 1394-1399.
- 88Wood J, Jenkins S, Putrino D, et al. A smartphone application for reporting symptoms in adults with cystic fibrosis improves the detection of exacerbations: Results of a randomised controlled trial. J Cyst Fibros. 2020; 19: 271-276.
- 89Leemans G, Belmans D, Van Holsbeke C, et al. The effectiveness of a mobile high-frequency chest wall oscillation (HFCWO) device for airway clearance. Pediatr Pulmonol. 2020; 55: 1984-1992.
- 90Weiner GA, Forno E, Weiner DJ. The effects of high-frequency chest compression on end-tidal CO2. Pediatr Pulmonol. 2020; 55: 646-648.
- 91Helper N, Kodesh E, Sokol G, Hakimi R, Vilozni D, Efrati O. The benefits of mechanical insufflator-exsufflator compared to autogenic drainage in adults with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 3046-3052.
- 92Reisi M, Modaresi MR, Aghaii Z, et al. Efficacy and safety of oral sildenafil in cystic fibrosis children with mild to moderate lung disease. Pediatr Pulmonol. 2020; 55: 156-160.
- 93Barth P, Bruijnzeel P, Wach A, et al. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. J Cyst Fibros. 2020; 19: 299-304.
- 94Reihill J, Moffitt K, Douglas L, Stuart Elborn J, Jones A, Lorraine Martin S. Sputum trypsin-like protease activity relates to clinical outcome in cystic fibrosis. J Cyst Fibros. 2020; 19: 647-653.
- 95Goss CH, Jain R, Seibold W, et al. An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF(TM) 1. ERJ Open Res. 2020; 6.
- 96Kevat AC, Carzino R, Vidmar S, Ranganathan S. Glycoprotein A as a biomarker of pulmonary infection and inflammation in children with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 401-406.
- 97Wijker NE, Vidmar S, Grimwood K, et al. Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort. Eur Respir J. 2020; 55:1901694.
- 98Loukou I, Moustaki M, Sardeli O, Plyta M, Douros K. Association of vitamin D status with lung function measurements in children and adolescents with cystic fibrosis. Pediatr Pulmonol. 2020; 55: 1375-1380.
- 99Mauch RM, Hentschel J, Aanaes K, et al. Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients. Pediatr Pulmonol. 2020; 55: 959-967.
Citing Literature
